Acute Lymphocytic Leukemia Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight

 The Acute Lymphocytic Leukemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Acute Lymphocytic Leukemia Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Lymphocytic Leukemia Market.

Some of the key takeaways from the Acute Lymphocytic Leukemia Pipeline Report:

• Companies across the globe are diligently working toward developing novel Acute Lymphocytic Leukemia treatment therapies with a considerable amount of success over the years. 
• Acute Lymphocytic Leukemia companies working in the treatment market are Nanjing Bioheng Biotech, Apamistamab Actinium Pharmaceuticals, Cellectis S.A., Autolus Limited, Takara Bio Inc., AbbVies, Janssen Research & Development, LLC, Jazz Pharmaceuticals, Orca Biosystems, Inc., Juventas Cell Therapy/CASI Pharmaceuticals, AbbVie, Jazz Pharmaceuticals, Autolus, AbbVie, Cellectis, and others, are developing therapies for the Acute Lymphocytic Leukemia treatment 

• Emerging Acute Lymphocytic Leukemia therapies such as – CTA30X, 131-I, UCART22, AUTO1, TBI-1501, Navitoclax, Daratumumab, CPX-351, Orca-T, Inaticabtagene autoleucel, Venetoclax, CPX-351, Obecabtagene autoleucel, Navitoclax, UCART22, and others are expected to have a significant impact on the Acute Lymphocytic Leukemia market in the coming years.   
• In February 2023, At the 2023 Transplantation & Cellular Therapy Meetings ofASTCT and CIBMTR, Orca Bio announced that data from the company’s investigational high-precision cell therapy programmes, OrcaT and Orca-Q, were given in three oral presentations. Positive Orca-T trial results were given for patients with acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), myelodysplastic syndromes (MDS), and other haematological malignancies in the single-center Phase 2 and multi-center Phase 1b trials
• In February 2023, OSE Immunotherapeutics SA provided a general update on the drug, which is being developed in immuno-inflammation through two ongoing Phase II clinical trials in Ulcerative Colitis (sponsor OSE) and in primary Sjögren’s Syndrome (sponsor Servier), as well as in haematology where promising preclinical data have been published online in the peer-reviewed “The Journal of Immunology.”The very aggressive tumour Acute Lymphoblastic Leukaemia (ALL), which develops from B or T cell progenitors, has also shown excellent therapeutic potential for OSE-127
• In December 2022, The Centre for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted Inaticabtagene Autoleucel (CNCT19 Injection) Priority Review Status in response to the acceptance of the New Drug Application (NDA) for the treatment of adult patients with relapsed and refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL)
• In June 2022, “A Randomised Phase III Trial of Patients with Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation with Either Orca-T, a Tcell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft” is the name of the study that Orca Biosystems, Inc. started

Acute Lymphocytic Leukemia Overview

An abnormal buildup of white blood cells (leukaemia cells) in the bone marrow causes acute lymphocytic leukaemia (ALL), also known as acute lymphoblastic leukaemia and acute lymphoid leukaemia. The leukaemia cells that leukaemia cannot completely mature replace healthy cells that create functional lymphocytes when ALL advances quickly.

Get a Free Sample PDF Report to know more about Acute Lymphocytic Leukemia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/acute-lymphocytic-leukemia-all-pipeline-insight

Emerging Acute Lymphocytic Leukemia Drugs Under Different Phases of Clinical Development Include:

• CTA30X: Nanjing Bioheng Biotech
• 131-I: Apamistamab Actinium Pharmaceuticals
• UCART22: Cellectis S.A.
• AUTO1: Autolus Limited
• TBI-1501: Takara Bio Inc.
• Navitoclax: AbbVies
• JZP-341: Jazz Pharmaceuticals
• Daratumumab: Janssen Research & Development, LLC
• CPX-351: Jazz Pharmaceuticals
• JZP-458: Jazz Pharmaceuticals
• Orca-T: Orca Biosystems, Inc.
• Inaticabtagene autoleucel: Juventas Cell Therapy/CASI Pharmaceuticals
• Venetoclax: AbbVie
• Obecabtagene autoleucel: Autolus

Route of Administration

Acute Lymphocytic Leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous.
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Acute Lymphocytic Leukemia Pipeline Therapeutics Assessment

• Acute Lymphocytic Leukemia Assessment by Product Type
• Acute Lymphocytic Leukemia By Stage and Product Type
• Acute Lymphocytic Leukemia Assessment by Route of Administration
• Acute Lymphocytic Leukemia By Stage and Route of Administration
• Acute Lymphocytic Leukemia Assessment by Molecule Type
• Acute Lymphocytic Leukemia by Stage and Molecule Type

DelveInsight’s Acute Lymphocytic Leukemia Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Acute Lymphocytic Leukemia product details are provided in the report. Download the Acute Lymphocytic Leukemia pipeline report to learn more about the emerging Acute Lymphocytic Leukemia therapies

Some of the key companies in the Acute Lymphocytic Leukemia Therapeutics Market include:

Key companies developing therapies for Acute Lymphocytic Leukemia are – PersonGen BioTherapeutics, Takara Bio Inc., Cellectis S.A., AbbVie, Autolus Limited, Juventas Cell Therapy Ltd., Orca Biosystems, Inc., Sanofi, Beijing Immunochina Medical Science & Technology Co., Ltd., Actinium Pharmaceuticals, Nanjing Bioheng Biotech Co., Ltd., Legend Biotech, Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Kymera Therapeutics, PeproMene Bio, Inc., Takeda Oncology, OneChain Immunotherapeutics, JW Therapeutics, Jazz Pharmaceuticals, Novartis, BRL Medicine, Meryx, Inc.,  Syndax Pharmaceuticals, Janssen Research & Development, LLC, Daiichi Sankyo Company, SecuraBio, Fate Therapeutics, In8bio Inc.,  Newave Pharmaceutical Inc, AstraZeneca,  Biomea Fusion Inc., Karyopharm Therapeutics Inc, Nkarta Inc., Athenex, Inc., ERYtech Pharma, Chongqing Precision Biotech Co., Ltd, Incyte Corporation, BioLineRx, Ltd, OSE Immunotherapeutics, Aleta Biotherapeutics, CalciMedica, Inc., Cabaletta Bio, Hebei Senlang Biotechnology, and others.

Acute Lymphocytic Leukemia Pipeline Analysis:

The Acute Lymphocytic Leukemia pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Lymphocytic Leukemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Lymphocytic Leukemia Treatment.
• Acute Lymphocytic Leukemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Lymphocytic Leukemia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Acute Lymphocytic Leukemia drugs and therapies

Acute Lymphocytic Leukemia Pipeline Market Drivers

• Increase in the prevalence of Acute lymphocytic leukemia (ALL), increasing Research and Development activities are some of the important factors that are fueling the Acute Lymphocytic Leukemia Market.

Acute Lymphocytic Leukemia Pipeline Market Barriers

• However, Cost associated with the treatment, side effects associated with the treatment options and other factors are creating obstacles in the Acute Lymphocytic Leukemia Market growth.

Scope of Acute Lymphocytic Leukemia Pipeline Drug Insight    

• Coverage: Global
• Key Acute Lymphocytic Leukemia Companies: Nanjing Bioheng Biotech, Apamistamab Actinium Pharmaceuticals, Cellectis S.A., Autolus Limited, Takara Bio Inc., AbbVies, Janssen Research & Development, LLC, Jazz Pharmaceuticals, Orca Biosystems, Inc., Juventas Cell Therapy/CASI Pharmaceuticals, AbbVie, Jazz Pharmaceuticals, Autolus, AbbVie, Cellectis, and others
• Key Acute Lymphocytic Leukemia Therapies: CTA30X, 131-I, UCART22, AUTO1, TBI-1501, Navitoclax, Daratumumab, CPX-351, Orca-T, Inaticabtagene autoleucel, Venetoclax, CPX-351, Obecabtagene autoleucel, Navitoclax, UCART22, and others
• Acute Lymphocytic Leukemia Therapeutic Assessment: Acute Lymphocytic Leukemia current marketed and Acute Lymphocytic Leukemia emerging therapies
• Acute Lymphocytic Leukemia Market Dynamics: Acute Lymphocytic Leukemia market drivers and Acute Lymphocytic Leukemia market barriers 

Request for Sample PDF Report for Acute Lymphocytic Leukemia Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services